Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research

News | Heart Failure

ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

October 7, 2022 — ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed ...

October 07, 2022

Results presented at the Heart Failure Society of America Annual Scientific Meeting

News | Heart Failure

Cleveland Clinic-Led Trial Finds That Increasing Salt Intake Does Not Affect Patients Hospitalized with Congestive Heart Failure During Treatment

October 6, 2022 — Findings from a Cleveland Clinic-led trial show that increasing the salt intake by mouth for patients ...

October 06, 2022

Rutgers study finds post-surgical hospitalization rates from left ventricular assist devices varied by socioeconomic factors

News | Heart Failure

Lower-Income Patients with Heart Pumps More Likely Hospitalized with Major Bleeding, Infection or Heart Failure

October 6, 2022 — The complications experienced by heart failure patients implanted with a left ventricular assist ...

October 06, 2022

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from ...

October 05, 2022

New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure

News | Heart Failure

New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100 Lowers Hospital Length of Stay by 55%

October 4, 2022 — Newswise — Daxor Corporation, a global leader in blood volume measurement technology, today announces ...

October 04, 2022

News | Cardiovascular Clinical Studies

New Analysis of Soloist-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

October 4, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3out ...

October 04, 2022

12 month data from The PRECISE Trial, the first global, prospective, randomized trial comparing diagnosis and evaluation pathways for stable chest pain, will be presented at the AHA 2022 Scientific Sessions.

News | AHA

HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions

October 4, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heart care, announced that the results of the ...

October 04, 2022

The stage is set for the American Heart Association (AHA) Scientific Sessions 2022, to be held November 5-7 at McCormick Place in Chicago, and virtually.

News | AHA

AHA Scientific Sessions 2022 Program, Late-breakers Announced

October 4, 2022 — The American Heart Association (AHA) Scientific Sessions 2022 is set for November 5-7 at McCormick ...

October 04, 2022

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home

News | Heart Failure

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products ...

October 03, 2022

Researchers at Mayo Clinic used artificial intelligence (AI) to evaluate patients’ electrocardiograms (ECGs) in a targeted strategy to screen for atrial fibrillation, a common heart rhythm disorder

News | Artificial Intelligence

AI-guided Screening Uses ECG Data to Detect a Hidden Risk Factor for Stroke

September 29, 2022 — Researchers at Mayo Clinic used artificial intelligence (AI) to evaluate patients’ electrocardiogra ...

September 29, 2022

Higher blood levels of collagen-derived molecule predict worse outcomes

News | Heart Failure

Penn Study Identifies New Prognostic Biomarker for Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

September 29, 2022

Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups

News | Stents Bioresorbable

BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold

September 27, 2022 — BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

September 27, 2022

a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.

News | Cardiogenic Shock

Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

September 27, 2022

UC San Diego researchers have created the first diagnostic tool able differentiate between two similar pediatric inflammatory conditions, using a novel artificial intelligence-guided algorithm

News | Coronavirus (COVID-19)

How to Tell the Difference between Kawasaki Disease and MIS-C

September 26, 2022 — Kawasaki disease (KD) is the leading cause of acquired heart disease in children in developed ...

September 26, 2022

Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment

News | Structural Heart

Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ( ...

September 26, 2022